- San Antonio, Texas- based GenSpera (GNSV) is a biotechnology company engaged in the development of targeted prodrug therapies for the treatment of human solid tumor cancers.
- The company’s drug development portfolio is based on a potential first in class, plant derived cytotoxin named thapsigargin, which is isolated from the seeds of a plant that grows naturally in countries around the Mediterranean.
- The Company’s lead drug candidate, G-202, is a prodrug formulation of a thapsigargin based cytotoxin that is bioactivated by the enzyme Prostate Specific Membrane Antigen (PSMA).
“The number of IPOs at least doubled in each sector and rebounded big exit M&A soared 50%. This environment led to record high potential distributions in 2014, topping $20 billion”
“This environment led to record high potential distributions in 2014, topping $20 billion. This is the largest return on investment measured since SVB began tracking the information a decade ago”
Source: Jonathan Norris, Kristina Peralta, “Trends in Healthcare Investments and Exits 2015,” SVB
M&A Driven Events
“By the 2006-2010 period, almost all of the exits, upwards of 75% – regardless of size – were M&A driven events. The recent IPO window (2013/14) pushes the data a bit, but not enough to eliminate the dominance of M&A exits: More than 60% of the big >250M exits in our space in the last few years have been M&A.”
- “IPOs used to be the only real game in town. Driving 67% of the exits and over 82% of the >250M exits in the late 1990s.”
- “The share of big exits vs. all exits contributed by either path has converged over time. In the last 7 years, roughly identical percentages exits in the two charts above, suggesting that the relative contributions of IPOs and M&As at big and small valuations are similar.”
Source: Bruce Booth, “Acquisitions As the Silent Partner in Biotech Liquidity: IPO Vs. M&A Exit Paths,” Forbes, 10/27/1014
Two Recent Spectacular Wins!
Alios acquisition by J&J for $1.75B
Seragon’s purchase by Roche/Genentech for $725M upfront and $1B in earn outs
Bruce Booth, “Acquisitions As the Silent Partner in Biotech Liquidity: IPO Vs. M&A Exit Paths,” Forbes, 10/27/1014, NVCA